Adenovirus p53 gene therapy.

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Dysfunctional tumor suppressor genes are common in human cancers.
• Gene transfer using adenoviral vectors can introduce functional tumor suppressor genes into cancer cells.
• The p53 tumor suppressor gene plays a critical role in cell cycle regulation and apoptosis.

Purpose of the Study:

• To evaluate the efficacy and safety of adenoviral-mediated p53 gene therapy for cancer treatment.
• To assess the potential of Ad-p53 as a monotherapy or in combination with conventional treatments.
• To investigate the molecular mechanisms underlying Ad-p53 therapy, including transgene expression and pathway activation.

Main Methods:

• Intratumoral injection of a replication-defective adenovirus expressing p53 (Ad-p53) in preclinical cancer models.
• Assessment of tumor growth arrest, apoptosis induction, and overall survival.
• Analysis of p53 transgene expression levels and activation of downstream p53 pathway genes.
• Evaluation of safety profile and potential combination effects with radiation and chemotherapy.

Main Results:

• Ad-p53 injections demonstrated an excellent safety profile.
• Monotherapy with Ad-p53 mediated tumor regression and growth arrest.
• Ad-p53 therapy overcame resistance and enhanced the effectiveness of radiation and chemotherapy.
• High-level expression of the p53 transgene was observed, activating other genes in the p53 pathway.

Conclusions:

• Adenovirus-mediated p53 gene therapy represents a proof-of-principle for effective tumor suppressor gene therapy.
• Ad-p53 holds significant potential as a targeted therapy for various human cancers.
• This approach offers a new paradigm in cancer treatment, potentially improving outcomes when used alone or in combination therapies.